M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors
- PMID: 2452877
M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors
Abstract
The interactions between dopamine and muscarinic receptor subtypes coupled to adenylate cyclase in superfused rat neostriatal slices were investigated using the efflux of cyclic AMP, in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, as a highly sensitive parameter of cyclic AMP production. Cyclic AMP efflux induced by simultaneous activation of (stimulatory) D-1 and (inhibitory) D-2 dopamine receptors by dopamine was reduced profoundly by the muscarinic receptor agonist oxotremorine and by inhibition of acetylcholinesterase with physostigmine, but not by the M-1 muscarinic receptor agonist McN-A-343. In contrast, upon blockade of D-2 receptors with (-)-sulpiride, dopamine-stimulated cyclic AMP efflux was inhibited by oxotremorine and physostigmine as well as by McN-A-343. Cyclic AMP efflux induced by isoprenaline, adenosine or vasoactive intestinal peptide was not affected by oxotremorine. The M-1 receptor-selective antagonist pirenzepine, unlike the nonselective antagonist atropine, was about 10 times less potent in antagonizing the inhibitory effects of (a near-maximally effective concentration of) oxotremorine upon simultaneous D-1 and D-2 receptor activation that upon selective D-1 receptor activation (i.e., upon blockade of D-2 receptors). In the latter case, pirenzepine was about 5 times more effective as an antagonist when muscarinic receptors were activated by McN-A-343 than upon exposure of the slices to oxotremorine or physostigmine, whereas the potency of atropine was independent of the agonist used.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Postsynaptic integration of cholinergic and dopaminergic signals on medium-sized GABAergic projection neurons in the neostriatum.Brain Res Bull. 1998 Apr;45(6):607-13. doi: 10.1016/s0361-9230(97)00460-7. Brain Res Bull. 1998. PMID: 9566505
-
Mu- and delta-opioid receptor-mediated inhibition of adenylate cyclase activity stimulated by released endogenous dopamine in rat neostriatal slices; demonstration of potent delta-agonist activity of bremazocine.J Pharmacol Exp Ther. 1989 Jun;249(3):864-8. J Pharmacol Exp Ther. 1989. PMID: 2543814
-
Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.J Pharmacol Exp Ther. 1985 Mar;232(3):608-16. J Pharmacol Exp Ther. 1985. PMID: 2579230
-
The pharmacology of McN-A-343.Pharmacol Ther. 2012 Aug;135(2):216-45. doi: 10.1016/j.pharmthera.2012.05.008. Epub 2012 May 27. Pharmacol Ther. 2012. PMID: 22643681 Review.
-
Cardioselective muscarinic antagonists.Fed Proc. 1987 Jun;46(8):2523-35. Fed Proc. 1987. PMID: 3036606 Review. No abstract available.
Cited by
-
New perspectives in signaling mediated by receptors coupled to stimulatory G protein: the emerging significance of cAMP efflux and extracellular cAMP-adenosine pathway.Front Pharmacol. 2015 Mar 24;6:58. doi: 10.3389/fphar.2015.00058. eCollection 2015. Front Pharmacol. 2015. PMID: 25859216 Free PMC article. Review.
-
Positive coupling of cholinergic muscarinic receptors to adenylate cyclase activity in membranes of rat olfactory bulb.Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):107-9. doi: 10.1007/BF00178981. Naunyn Schmiedebergs Arch Pharmacol. 1990. PMID: 2402299
-
Age-related changes in signal transduction. Implications for neuronal transmission and potential for drug intervention.Drugs Aging. 1994 Nov;5(5):366-90. doi: 10.2165/00002512-199405050-00006. Drugs Aging. 1994. PMID: 7833590 Review.